Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy

Related

• 

  Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

  Baruch D. Kuppermann, MD, PhD

  Annual Meeting Talks

  2020

• 

  Expert Panel: Socioeconomics

  Linda A. Lam, MD, MBA, FASRS

  Ella H Leung, MD

  Mohsin H. Ali, MD

  Hasenin Al-khersan, MD

  Miguel A. Busquets, MD, FACS

  Annual Meeting Talks

  2024

• 

  Do Anti-VEGF Injections Affect the Development of Neovascular AMD in Fellow Eyes? A Meta-analysis of Clinical Trials

  Robert L. Avery, MD

  Annual Meeting Talks

  2018